Lidokain Aguettant (Lidocaine Hydrochloride)

Lidokain Aguettant is a local anesthetic used to achieve temporary loss of sensation in targeted tissues.

• Infiltration anesthesia: provides localized numbness for minor surgical procedures.
• Intradermal anesthesia: enables precise skin anesthesia for diagnostic or cosmetic interventions.
• Intravenous regional anesthesia: facilitates a Bier block for limb surgeries by producing reversible nerve blockade.

• Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, inhibiting the influx of sodium ions required for depolarization. This prevents the initiation and propagation of action potentials, resulting in a reversible loss of sensory and motor function in the area where the drug is administered.

Lidokain Aguettant may cause adverse reactions at the injection site or systemically.

Common Side Effects

• Burning or stinging sensation at the injection site.
• Tingling or numbness extending beyond the intended area.
• Mild swelling or erythema around the injection site.
• Transient dizziness or light‑headedness.
• Nausea or mild headache.

Serious or Rare Side Effects

• Systemic toxicity presenting as seizures, confusion, or loss of consciousness.
• Cardiovascular effects such as arrhythmias, hypotension, or cardiac arrest.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Methemoglobinemia, a rare disorder affecting oxygen transport.
• Persistent numbness or motor weakness beyond the expected duration.

When using Lidokain Aguettant, clinicians should observe several safety measures.

• Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics.
• Dosage calculation: base the dose on patient weight, procedure type, and route of administration.
• Cardiovascular monitoring: observe for signs of toxicity, especially during intravenous use.
• Hepatic function: use with caution in patients with impaired liver metabolism.
• Pregnancy and lactation: assess risk‑benefit ratio before administration.
• Store at ambient temperature: keep in the original container, protect from light and moisture.

Lidokain Aguettant can interact with other medications, requiring careful management.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): increase risk of cardiotoxicity.
• Beta‑blockers (e.g., propranolol): may potentiate cardiac depression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise systemic lidocaine concentrations.

Moderate Interactions (Monitor Closely)

• Concurrent use of other local anesthetics: cumulative toxicity risk.
• Epinephrine: may prolong anesthetic effect but also increase systemic absorption.
• Diuretics (e.g., furosemide): may alter plasma protein binding and affect drug levels.